Panagiotidis, Georgios-DimitriosGeorgios-DimitriosPanagiotidisMüller, ChristinChristinMüllerBinder, MarcoMarcoBinderWeber, FriedemannFriedemannWeber2024-02-062024-02-062023https://jlupub.ub.uni-giessen.de/handle/jlupub/18958http://dx.doi.org/10.22029/jlupub-18319Influenza A virus (FLUAV) is a significant human pathogen. In silico structural analysis (PMID 28628827) has suggested that the FDA-approved drug paliperidone interferes with the binding of the FLUAV polymerase subunit PB2 to the nucleoprotein NP. We found that paliperidone inhibits FLUAV A/PR/8/34 early after infection of canine MDCK II, human A549, and human primary bronchial cells, but not at late time points. No effect was detectable against the strains A/Hamburg/05/2009 and A/WSN/33. Moreover, paliperidone indeed disturbed the interaction between the PB2 and the NP of A/PR/8/34 and reduced early viral RNA and protein synthesis by approximately 50%. Thus, paliperidone has measurable but transient and virus-strain-restricted effects on FLUAV.enNamensnennung 4.0 Internationalddc:630